Last update 23 Jan 2025

Vintafolide

Overview

Basic Info

Drug Type
Small molecule-drug conjugates
Synonyms
VYNFINIT, Vintafolide (USAN/INN)
+ [1]
Mechanism
FOLR1 agonists(Folate receptor alpha agonists), FOLR2 agonists(Folate receptor beta agonists), Tubulin modulators
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC86H109N21O26S2
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N
CAS Registry742092-03-1
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2--
Advanced Triple-Negative Breast CarcinomaPhase 1-01 Apr 2014
Advanced cancerPhase 1-01 Dec 2012
Platinum-Resistant Ovarian CarcinomaPhase 1-22 Apr 2011
Non-small cell lung cancer stage IIIBPhase 1-01 Mar 2011
Solid tumorPhase 1
US
31 Dec 2009
Adenocarcinoma of LungPhase 1-01 Aug 2007
Endometrial CarcinomaPhase 1-01 Aug 2007
Relapsed Solid NeoplasmPhase 1
US
01 Mar 2006
Ovarian CancerPreclinical
EU
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
49
idsjyhpreh(tkespuhbdz) = iqjfhwqvlr yuturuhtwn (jwoorgytjx )
-
01 Apr 2014
99mTc-etarfolatide
idsjyhpreh(tkespuhbdz) = yomrascjdn yuturuhtwn (jwoorgytjx )
Phase 2
149
(lakjkywjnw) = opwvrlpfdc vieqstpfyg (hexqxjbklk )
Positive
10 Dec 2013
PLD alone
(lakjkywjnw) = ppwpmawbol vieqstpfyg (hexqxjbklk )
Phase 3
441
(cwxyyiijyh) = raosvzhggr kkaazpybrw (vsgzwfasdx )
-
20 May 2013
PLD + placebo
(cwxyyiijyh) = hlfrinbabr kkaazpybrw (vsgzwfasdx )
Phase 2
157
(ltexayfbrg) = tzxstvyobq mrcwnouhlg (hjxoafdcdu )
-
20 May 2013
PLD alone
(ltexayfbrg) = ndwwfffgnj mrcwnouhlg (hjxoafdcdu )
Phase 1
Solid tumor
FR-positive tumor xenografts
-
iemuannanh(lphjfkgemr) = Constipation was the dose-limiting toxicity with both routes hgaqwwhdrm (dmyinzappq )
-
10 Nov 2012
Phase 2
45
(EC20++)
(rwvrterzej) = hnezzblpno ducxpzaxrj (xtnjufbcai )
-
20 May 2010
(EC20+)
(rwvrterzej) = hfgkomsrii ducxpzaxrj (xtnjufbcai )
Phase 1
-
mwodvyurfi(eddbcscpre) = Constipation was the most common and clinically relevant toxicity induced by EC145 znzmsbrlmu (kubvpoyimg )
-
01 Dec 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free